Skip to content
TrialScanner

NCT03125200

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

Phase 1TerminatedADCTLead

Registry record

Lead sponsor
ADC Therapeutics S.A.
Conditions
Breast Cancer; Non Small Cell Lung Cancer; GastroEsophageal Cancer; Bladder Cancer
Primary completion
Apr 5, 2018Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03125200 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03125200: Study of ADCT-502 in... | TrialScanner